GLPwatch

GLP-1 Analogue, Exendin-4, Modulates MAPKs Activity but not the Heat Shock Response in Human HepG2 Cells.

Proteomics Clin Appl · 2018

Last updated 2026-05-28

In lab tests on human liver cells, the GLP-1 drug exendin-4 did not change levels of heat shock proteins (HSP60, HSP72, HSP90, and GRP78) under stress conditions. However, it increased activity of certain signaling proteins (JNK, ERK1/2, and p38) after short exposure, but reduced their activity after 24 hours. The drug also affected other signaling pathways (EIF2, ILK, PKA, and Rho) linked to energy balance.

AI summary of the abstract below.

JournalProteomics Clin Appl, 2018
Citations6
Relative citation ratio0.30
NIH percentile19
Molecules
Conditions studied Mash

Abstract

PURPOSE: Glucagon-like peptide-1 (GLP-1) analogues reduce ER stress and inflammation in key metabolic organs, including the liver. However, their effects on heat shock response (HSR) and mitogen-activated protein kinases (MAPKs) have not yet been elucidated. In the present study, we investigate whether the GLP-1 analogue, exendin-4, triggers the expression of HSR and increases MAPK activity under metabolic stress. EXPERIMENTAL DESIGN: The effects of exendin-4 in the presence or absence of palmitic acid (PA; 400 μm) or glucose (30 mm) in the HepG2 liver cell line are assessed using Western blots, quantitative real-time PCR, and label-free proteomics. RESULTS: Heat shock proteins (HSP60, HSP72, HSP90, and GRP78) and other chaperones are not significantly affected by exendin-4 under the conditions tested. In contrast, the presence of exendin-4 alone increases the MAPK phosphorylation levels (JNK, ERK1/2, and p38). For short incubation periods, in the presence of PA or glucose, treatment with exendin-4 exhibits limited effects but significantly attenuates MAPK phosphorylation after a 24-h incubation. Interestingly, canonical signaling pathways, such as EIF2, ILK, PKA, and Rho, are modulated by exendin-4. CONCLUSION AND CLINICAL RELEVANCE: Identifying new pathways modulated by GLP-1 analogues will provide further insights into their benefits beyond their currently recognized roles in glycemic control, such as MAPK activity, energy homeostasis, and body weight decrease.

Verbatim abstract via PubMed 29105359 ↗